TriangleNCT01315873 · REGISTRY CONDITION SEARCH
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2018-02-07
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4 of each cycle, with bortezomib being given first, before each dose of bendamustine. Each cycle will be 28 days long, so patients will be treated the first week of each cycle and then have 3 weeks 'off' (without any treatment). Disease assessments will be performed on day 22 of each cycle. Patients will receive the study drugs until their disease progresses or they are withdrawn from the study. In other studies, bendamustine seems to work well with other drugs. Thus, this study hopes to show that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Voluntary written informed consent 2. Age 18 years or older 3. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. 4. Male subject agrees to use an acceptable method for contraception for the duration of the study. 5. Diagnosis of multiple myeloma based on standard criteria as follows: Major Criteria * Plasmacytomas on tissue biopsy * Bone marrow plasmacytosis (\>30% plasma cells) * Monoclonal immunoglobulin spike on serum electrophoresis (IgG \>3.5 g/dL or IgA \>2.0 g/dL) or kappa or lambda light chain excretion \>1 g/day on 24 hour urine protein electrophoresis Minor Criteria * Bone marrow plasmacytosis (10 to 30% plasma cells) * Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria * Lytic bone lesions * Normal IgM \<50 mg/dL, IgA \<100 mg/dL, or IgG \<600 mg/dL * Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma: * Any two of the major criteria or * 1 major plus 2 minor criteria. 6. Measurable disease, defined as a monoclonal immunoglobulin spike (M-Spike) on serum electrophoresis of ≥1 g/dL and/or urine monoclonal immunoglobulin spike of ≥200 mg/24 hours. Non-secretors must have measurable protein by Freelite or measurable disease by plasmacytoma to be eligible. 7. Patients must have refractory myeloma as defined by a greater than 25% increase in their M-protein. They should have progressed on bortezomib. 8. Karnofsky performance status ≥50 9. Patients treated with local radiotherapy with or without a brief exposure to steroids are eligible. Patients who require radiotherapy should have entry to the protocol deferred until the radiotherapy is completed by at least 4 weeks prior to initiation of study drug. 10. Meets the following pretreatment laboratory criteria at baseline (Day 1 of Cycle 1, before study drug administration) * Absolute neutrophil count ≥1 x 10\^3/uL * Platelet count ≥75 x 10\^3/uL * Hemoglobin ≥8.0 g/dL * Calculated or measured CrCL ≥ 40 mL/min * AST or ALT and total bilirubin \< 3 x ULN 11. Echocardiogram with a \>50% Ejection Fraction Exclusion Criteria: Patients meeting any of the following exclusion criteria are not to be registered on study: 1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) 2. Plasma cell leukemia 3. Receiving steroids daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis 4. Infection not controlled by antibiotics 5. HIV infection. Patients should provide consent for HIV testing according to the institution's standard practice. 6. Known active hepatitis B or C 7. New York Hospital Association (NYHA) Class III or IV heart failure, Echo or MUGA ejection fraction \< 40% (if known), or EKG evidence of acute ischemic disease 8. Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol 9. Second malignancy requiring treatment in the last 3 years 10. Patient has a calculated or measured creatinine clearance of \<40 mL/min within 14 days before enrollment 11. Patient has \>Grade 2 peripheral neuropathy within 14 days before enrollment 12. Patient has hypersensitivity to bortezomib, boron or mannitol and bendamustine 13. Positive pregnancy test in women of childbearing potential or subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum betaa human chorionic gonadotropin test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. 14. Patient has received other investigational drugs with 14 days before enrollment 15. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. 16. Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: Bendamustine
- Drug: Bortezomib
- label
- Bortezomib and Bendamustine
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Bortezomib and Bendamustine
- description
- On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle. Patients will be treated until disease progression after at least one cycle of treatment.
- name
- Bendamustine
- other Names
- Bendamustine HCl
- Treanda
- type
- DRUG
- arm Group Labels
- Bortezomib and Bendamustine
- description
- On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle. Patients will be treated until disease progression after at least one cycle of treatment.
- name
- Bortezomib
- other Names
- Velcade
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 24
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life.The IWG criteria define 4 aspects of responses based on treatment goals: (1) altering the natural history of the disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4)Quality of Life (QOL)
- measure
- Percent Change Response Rate (Partial Response or Better After 2 Cycles) Following Treatment With Bortezomib and Bendamustine
- time Frame
- 8 weeks
- secondary Outcomes
- description
- Study toxicity will be measured on an ongoing basis, no less then once per 28-day cycle.
- measure
- Toxicity of This Regimen.
- time Frame
- Every 4 weeks.
- description
- Time from response to relapse. Response would have been assessed using European Group for Blood and Marrow Transplantation (EBMT) criteria modified to include near complete remission (nCR) and very good partial remission (VGPR
- measure
- Duration of Response of This Regimen.
- time Frame
- from initial response to relapse, up to 100 weeks.
Full study description
- brief Summary
- Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4 of each cycle, with bortezomib being given first, before each dose of bendamustine. Each cycle will be 28 days long, so patients will be treated the first week of each cycle and then have 3 weeks 'off' (without any treatment). Disease assessments will be performed on day 22 of each cycle. Patients will receive the study drugs until their disease progresses or they are withdrawn from the study. In other studies, bendamustine seems to work well with other drugs. Thus, this study hopes to show that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
- detailed Description
- Patients with relapsed and refractory myeloma who have a measurable paraprotein in the serum or urine or measurable protein by Freelite or measurable disease by plasmacytoma will be given a combination of bendamustine and bortezomib each cycle. Response rate (PR or better after 2 cycles) and duration of response will be assessed. Therapy will be continued until disease progression. The bendamustine would be used in a day 1, day 4 dosing schedule after each dose of bortezomib to take advantage of the chemosensitizing properties of bortezomib. This minimizes the days of treatment to just the first week and allows rebound of blood counts. This will be a phase II trial with dose reduction as necessary. Bendamustine is a drug which appears to be non-cross-resistant with other alkylating agents in vitro and in vivo. Thus, we hypothesize that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-666bde9b5215c6626f90
- requested nct id
- NCT01315873
- primary nct id
- NCT01315873
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- d6b66ee88521ad8729f9ac7a505d3e6cc16c8add3d4b5b6cba2b427f6a1faa15
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-666bde9b5215c6626f90
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01315873
- occurrences
- context exact
- NCT01315873
- end
- 11
- exact text
- NCT01315873
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/182/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- adbb9ec83f27f53a5883dbc7ef58379270f3bca4e9eb3fa831710a2beebda8ad
Preserved source evidence · Not medical advice